Evan J. Lipson

21.6k total citations · 4 hit papers
126 papers, 7.7k citations indexed

About

Evan J. Lipson is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Evan J. Lipson has authored 126 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 32 papers in Immunology and 26 papers in Molecular Biology. Recurrent topics in Evan J. Lipson's work include Cancer Immunotherapy and Biomarkers (93 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (26 papers). Evan J. Lipson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (93 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (26 papers). Evan J. Lipson collaborates with scholars based in United States, Germany and Australia. Evan J. Lipson's co-authors include Charles G. Drake, Julie R. Brahmer, Suzanne L. Topalian, Janis M. Taube, William H. Sharfman, Dung T. Le, Jarushka Naidoo, Patrick M. Forde, F. Stephen Hodi and Drew M. Pardoll and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Immunology.

In The Last Decade

Evan J. Lipson

118 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

2016 452 citations Evan J. Lipson, F. Stephen Hodi et al. profile →
Evolutionary dynamics of cancer in response to targeted combination therapy

2013 433 citations Evan J. Lipson et al. profile →
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

2016 391 citations F. Stephen Hodi, Hussein A. Tawbi et al. Journal for ImmunoTherapy of Cancer profile →
Cardiovascular toxicities associated with immune checkpoint inhibitors

2019 342 citations Evan J. Lipson, Jarushka Naidoo et al. profile →

Peers

Countries citing papers authored by Evan J. Lipson

Since Specialization

Citations

This map shows the geographic impact of Evan J. Lipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan J. Lipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan J. Lipson more than expected).

Fields of papers citing papers by Evan J. Lipson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan J. Lipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan J. Lipson. The network helps show where Evan J. Lipson may publish in the future.

Co-authorship network of co-authors of Evan J. Lipson

This figure shows the co-authorship network connecting the top 25 collaborators of Evan J. Lipson. A scholar is included among the top collaborators of Evan J. Lipson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan J. Lipson. Evan J. Lipson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy 2025 ·British Journal of Dermatology ·Tomoko Akaike, (unknown), Daniel S. Hippe, Matthew W. Gilmour, (unknown), Alex Z. Fu, Neha Singh, (unknown), (unknown), Nasreen A. Vohra, E. D. Hall, Shailender Bhatia, Evan J. Lipson, Christopher D. Blosser, Paul Nghiem	0
2	Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update 2025 ·European Journal of Cancer ·Evan J. Lipson, F. Stephen Hodi, Hussein Tawbi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, (unknown), J. Menezes, Stéphane Dalle, Ana Arance, Caroline Gaudy‐Marqueste, Bingshu E. Chen, William T. Jackson, (unknown), Sonia Dolfi, Georgina V. Long	1
3	Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047 2025 ·Journal for ImmunoTherapy of Cancer ·Meredith M. Regan, Paolo A. Ascierto, Evan J. Lipson, (unknown), Andriy Moshyk, A. Selvan, Christopher D. Lao, Michael B. Atkins, David F. McDermott, Ravi Potluri, (unknown), (unknown), Georgina V. Long, (unknown), Hussein A. Tawbi, Dirk Schadendorf	0
4	1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses 2024 ·Annals of Oncology ·Danny Rischin, David Miller, Nikhil I. Khushalani, (unknown), (unknown), Evan J. Lipson, Friedegund Meier, (unknown), Paul Swiecicki, (unknown), (unknown), Axel Hauschild, Jennifer H. Choe, (unknown), (unknown), Lance Brennan, Melissa Mathias, Hee‐Sun Han, Matthew G. Fury, Neil D. Gross	2
5	Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. 2024 ·Journal of Clinical Oncology ·Paolo A. Ascierto, Reinhard Dummer, Caroline Gaudy‐Marqueste, Samantha Bowyer, Evan J. Lipson, Eleonora Ghisoni, Mark R. Middleton, (unknown), (unknown), (unknown), (unknown), (unknown), Georgina V. Long	15
6	Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC). 2024 ·Journal of Clinical Oncology ·Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher D. Lao, Jean‐Jacques Grob, Flavia Ejzykowicz, (unknown), (unknown), Zheng‐Yi Zhou, (unknown), Lisa Rosenblatt, Laura McDonald, (unknown), (unknown), Divya Patel, (unknown), Georgina V. Long	0
7	Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 2024 ·Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, (unknown), (unknown), Antonella Mazzei, Sonia Dolfi, Georgina V. Long	24
8	EPID-29. EPIDEMIOLOGICAL CHARACTERIZATION OF BRAIN METASTASES IN MELANOMA: A LARGE POPULATION BASED-STUDY FROM 2014-2024 2024 ·Neuro-Oncology ·(unknown), (unknown), (unknown), Kelly Jiang, (unknown), (unknown), David Kamson, Kristin J. Redmond, Govind Warrier, Evan J. Lipson, Xiaobu Ye, (unknown), Jordina Rincón-Torroella	1
9	First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data 2024 ·Journal of Clinical Oncology ·Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher D. Lao, Jean‐Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, (unknown), Zheng‐Yi Zhou, Yiqiao Xin, (unknown), Laura McDonald, (unknown), (unknown), Divya Patel, (unknown), Hussein A. Tawbi, Dirk Schadendorf	20
10	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. 2023 ·Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, (unknown), (unknown), (unknown), Sonia Dolfi, Georgina V. Long	7
11	Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma 2023 ·Cell Reports Medicine ·Julie S. Deutsch, Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban, Yasser Ged, Nirmish Singla, Toni K. Choueiri, Saurabh Gupta, Robert J. Motzer, David F. McDermott, Sabina Signoretti, Michael B. Atkins, Janis M. Taube	18
12	LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047 2023 ·Annals of Oncology ·Evan J. Lipson, Sonia Dolfi, Hao Tang, Helen Gogas, Hussein A. Tawbi, F. Stephen Hodi, Paolo A. Ascierto, (unknown), Dirk Schadendorf, Fernando Soto, Piotr Rutkowski, (unknown), Michele Maio, (unknown), Keyur Desai, Alice L. Yu, Korey Demers, (unknown), Georgina V. Long, Charlie Garnett‐Benson	3
13	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells 2022 ·Cancer Immunology Research ·Ashwin Somasundaram, Anthony R. Cillo, Caleb Lampenfeld, Creg J. Workman, Sheryl Kunning, (unknown), Maria A. Velez, Sonali Joyce, Michael Calderon, Rebekah Dadey, Dhivyaa Rajasundaram, Daniel P. Normolle, Simon C. Watkins, James G. Herman, John M. Kirkwood, Evan J. Lipson, Robert L. Ferris, Tullia C. Bruno, Dario A.A. Vignali	18
14	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery 2021 ·Cancer Immunology Research ·Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk, Elizabeth L. Engle, Benjamin Green, Peter Nguyen, Abha Soni, Julie E. Stein, Farah Succaria, Aleksandra Ogurtsova, Haiying Xu, Raphaël Gottardo, Robert A. Anders, Evan J. Lipson, Ludmila Danilova, Alexander S. Baras, Janis M. Taube	6
15	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors 2021 ·Clinical Cancer Research ·Fyza Y. Shaikh, James R. White, Joell J. Gills, Taiki Hakozaki, Corentin Richard, Bertrand Routy, Yusuke Okuma, Mykhaylo Usyk, Abhishek Pandey, Jeffrey S. Weber, Jiyoung Ahn, Evan J. Lipson, Jarushka Naidoo, Drew M. Pardoll, Cynthia L. Sears	27
16	Kidney retransplantation after anti–programmed cell death-1 (PD-1)–related allograft rejection 2020 ·American Journal of Transplantation ·Evan J. Lipson, Fizza Naqvi, Manisha J. Loss, Megan D. Schollenberger, Drew M. Pardoll, Jack Moore, Daniel C. Brennan	16
17	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade 2019 ·Clinical Cancer Research ·Julie E. Stein, Evan J. Lipson, Tricia R. Cottrell, Patrick M. Forde, Robert A. Anders, Ashley Cimino‐Mathews, Elizabeth D. Thompson, Mohamad E. Allaf, Mark Yarchoan, Josephine Feliciano, Hao Wang, Elizabeth M. Jaffee, Drew M. Pardoll, Suzanne L. Topalian, Janis M. Taube	92
18	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison 2017 ·Clinical Cancer Research ·Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Karen B. Bleich, Toby C. Cornish, Evan J. Lipson, Robert A. Anders, Janis M. Taube	109
19	Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results 2016 ·International Journal of Radiation OncologyBiologyPhysics ·Colette J. Shen, Doris Lin, Kristin J. Redmond, Katherine E. Link, (unknown), Jacqueline Douglass, Evan J. Lipson, William H. Sharfman, Chetan Bettegowda, Michael Lim, Lawrence Kleinberg	2
20	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma 2011 ·Clinical Cancer Research ·Evan J. Lipson, Charles G. Drake	434

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact